[Efficiency of tacrolimus therapy for perianal Crohn's disease].
Autor: | Nanaeva BA; State Coloproctology Research Center, Ministry of Health of Russia, Moscow, Russia., Vardanyan AV; State Coloproctology Research Center, Ministry of Health of Russia, Moscow, Russia., Khalif IL; State Coloproctology Research Center, Ministry of Health of Russia, Moscow, Russia. |
---|---|
Jazyk: | ruština |
Zdroj: | Terapevticheskii arkhiv [Ter Arkh] 2015; Vol. 87 (6), pp. 83-87. |
DOI: | 10.17116/terarkh201587683-87 |
Abstrakt: | Aim: To determine the efficacy of 0.1% tacrolimus ointment in patients with perianal Crohn's disease (CD). Subjects and Methods: This prospective randomized trial enrolled 20 patients with perianal CD as anal fissures and rectal fistulas. The inclusion criteria were rectovaginal or extrasphincteric fistulas and purulent leakages. A study group comprised 11 patients, including 9 with anal fissures and 2 with fistulas. A control group included 9 patients, including 8 with fissures and 1 with fistulas. The study group received systemic therapy with azathioprine 2 mg/kg/day and tacrolimus ointment 2 mg/day; the control group had systemic therapy with azathioprine 2 mg/kg/day, hormone ointment 1 mg/day, and metronidazole suppositories 250 mg/day. Control examination and perianal CD activity index (PCDAI) determination were done 6 and 12 weeks after therapy initiation. Results: At 6 weeks after beginning the study, local examination revealed the signs of anal fissure epithelialization in 5 (45.5%) of the 11 patients in the study group and in 3 (33.3%) of the 9 patients in the control one. At 12 weeks, fissure epithelialization and fistula obliteration were stated in 6 (54%) patients in the study group and in 3 (33%) of the 9 patients in the control group. At 12 weeks, PCDAI in the study and control groups was 2.00 and 4.44 scores (p = 0.01). Conclusion: The findings suggest that topical 0.1% tacrolimus ointment versus antibacterial suppositories and hormone ointments is effective in treating patients with perianal CD. Topical 0.1% tacrolimus ointment therapy caused a reduction in PCDAI. |
Databáze: | MEDLINE |
Externí odkaz: |